ML352

• CAT Number: I011316
• CAS Number: 1649450-12-3
• Molecular Formula: C21H29N3O4
• Molecular Weight: 387.48
• Purity: ≥95%
• Synonyms: (Z)-N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzimidic acid
• Target: Cholinesterase (ChE)
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: 4-methoxy-3-(1-methylpiperidin-4-yl)oxy-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]benzamide
• InChI: InChI=1S/C21H29N3O4/c1-14(2)18-12-17(28-23-18)13-22-21(25)15-5-6-19(26-4)20(11-15)27-16-7-9-24(3)10-8-16/h5-6,11-12,14,16H,7-10,13H2,1-4H3,(H,22,25)
• InChIKey: WBLVOWHFRUAMCP-UHFFFAOYSA-N
• SMILES: CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C

ML352(CAT: I011316) is a small molecule that acts as a potent and selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), which is involved in the regulation of intracellular levels cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE10A is mainly expressed in the striatum and is involved in the regulation of neuronal signaling pathways that are disrupted in neurological disorders such as Huntington’s disease and schizophrenia. By inhibiting PDE10A, ML352 increases the levels of cAMP and cGMP, which has potential therapeutic applications in the treatment of these neurological disorders. ML352 has been widely used as a research tool to study the role of PDE10A in neuronal signaling pathways and for the development of novel therapeutics.